Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Taro Edahiro; Hiroshi Ureshino; Ren Chishaki; Keita Fujino; Tatsuji Mino; Tetsumi Yoshida; Noriyasu Fukushima; Tatsuo Ichinohe

doi:10.2169/internalmedicine.1069-22

This article has now been updated. Please use the final version.

Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Taro Edahiro, Hiroshi Ureshino, Ren Chishaki, Keita Fujino, Tatsuji Mino, Tetsumi Yoshida, Noriyasu Fukushima, Tatsuo Ichinohe

Author information

Taro Edahiro
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Hiroshi Ureshino
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Japan
Ren Chishaki
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Keita Fujino
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Tatsuji Mino
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Tetsumi Yoshida
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
Noriyasu Fukushima
Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
Tatsuo Ichinohe
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan

Keywords: Gilteritinib, Acute myeloid leukemia, FLT3 mutation, Allogenic stem cell transplantation, graft-versus-leukemia effect, graft-versus-host disease

JOURNAL OPEN ACCESS Advance online publication

Article ID: 1069-22

DOI https://doi.org/10.2169/internalmedicine.1069-22

The final version of this article is now available: Vol. 62 (2023), No. 15 pp. 2243-2247

Details

Abstract

Patients with acute myeloid leukemia (AML) harboring FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication mutation are associated with a poor survival outcome, even those receiving allogeneic stem cell transplantation (Allo-SCT). An additional treatment strategy with allo-SCT is therefore required to reduce relapse in these patients. Gilteritinib is a specific FLT3 inhibitor that has shown clinical benefit for patients with relapsed and refractory (R/R) AML harboring FLT3 mutation. We herein report a 49-year-old woman with R/R AML who was successfully treated with pre- and post-transplant gilteritinib. Post-transplant gilteritnib yielded a durable response with possible exacerbation of graft-versus-host disease.

Corresponding author

Register with J-STAGE for free!